Cargando…

The (68)Ga/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

INTRODUCTION: A new therapeutic option for metastatic castration–resistant prostate cancer (mCRPC) of heavily pre-treated patients lies in (177)Lu-PSMA-617 radioligand therapy. METHODS: On the basis of PSMA-targeted (68)Ga-PSMA-11 PET/CT, 32 consecutive mCRPC patients were selected for (177)Lu-PSMA-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maffey-Steffan, Johanna, Scarpa, Lorenza, Svirydenka, Anna, Nilica, Bernhard, Mair, Christian, Buxbaum, Sabine, Bektic, Jasmin, von Guggenberg, Elisabeth, Uprimny, Christian, Horninger, Wolfgang, Virgolini, Irene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005064/ https://www.ncbi.nlm.nih.gov/pubmed/31776632 http://dx.doi.org/10.1007/s00259-019-04583-2

Ejemplares similares

Long-Term Survival and Value of (18)F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with (177)Lu-DOTATATE
por: Rodrigues, Margarida, et al.
Publicado: (2021)

Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT
por: Bayerschmidt, Steffen, et al.
Publicado: (2021)

(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
por: von Eyben, Finn E., et al.
Publicado: (2017)

Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
por: von Eyben, Finn Edler, et al.
Publicado: (2017)

Improved quality control of [(177)Lu]Lu-PSMA I&T
por: Kraihammer, Martin, et al.
Publicado: (2023)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2020)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry
por: Uijen, Maike J.M., et al.
Publicado: (2023)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Urinary excretion kinetics of [(177)Lu]Lu-PSMA-617
por: de Bakker, Maarten, et al.
Publicado: (2023)

(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

(177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Sanli, Yasemin, et al.
Publicado: (2021)

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
por: von Eyben, Finn Edler, et al.
Publicado: (2019)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

Extended therapy with [(177)Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation
por: Bilinski, Pretoria, et al.
Publicado: (2020)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020)

Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review
por: Heidegger, Isabel, et al.
Publicado: (2022)

Automated radiosynthesis of [(68)Ga]Ga‐PSMA‐11 and [(177)Lu]Lu‐PSMA‐617 on the iPHASE MultiSyn module for clinical applications
por: Wichmann, Christian W., et al.
Publicado: (2020)

[(177)Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography
por: Tönnesmann, Roswitha, et al.
Publicado: (2019)

Tumor uptake in glioblastoma multiforme after IV injection of [(177)Lu]Lu-PSMA-617
por: Kunikowska, Jolanta, et al.
Publicado: (2020)

2021: the year [(177)Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?: Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
por: Herrmann, Ken, et al.
Publicado: (2021)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

Molecular imaging and biochemical response assessment after a single cycle of [(225)Ac]Ac-PSMA-617/[(177)Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [(177)Lu]Lu-PSMA-617 monotherapy
por: Rosar, Florian, et al.
Publicado: (2021)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
por: Rumiantcev, Mikhail, et al.
Publicado: (2023)

Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
por: Groener, Daniel, et al.
Publicado: (2023)

Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
por: Groener, Daniel, et al.
Publicado: (2021)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Comparison of different methods for post-therapeutic dosimetry in [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Rosar, Florian, et al.
Publicado: (2021)

Characterization of Non-Specific Uptake and Retention Mechanisms of [(177)Lu]Lu-PSMA-617 in the Salivary Glands
por: Heynickx, Nathalie, et al.
Publicado: (2023)

Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUV(max) reference range for management of pancreatic neuroendocrine tumours
por: Virgolini, Irene, et al.
Publicado: (2016)

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Development and Validation of Analytical Methods for Radiochemical Purity of (177)Lu-PSMA-1
por: Orhon, Pauline, et al.
Publicado: (2022)

Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of (177)Lu-Labeled Peptide Analogs Targeting CCK2R
por: Hörmann, Anton Amadeus, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lfmh26g73leq90aciim8tk1te2